<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Alhzeimer_Disease - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    

    

    
    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Alhzeimer_Disease</span>
        </nav>

        <header class="page-header">
            <h1>Alhzeimer_Disease</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Neurodegenerative Disorder</span>
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0004975" target="_blank">
                        MONDO:0004975
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Dementia</span>
                
            </div>
            
        </header>

        <!-- Stats bar -->
        <div class="stats-bar">
            <div class="stat-item">
                <div class="stat-value">7</div>
                <div class="stat-label">Mechanisms</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Histopathology</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">6</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">8</div>
                <div class="stat-label">Genes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Treatments</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">2</div>
                <div class="stat-label">Subtypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
        </div>

        <!-- Classifications -->
        

        <!-- Subtypes -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #eef2ff; color: #4f46e5;">◆</div>
                <h2 class="card-title">Subtypes</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box subtype-box">
                <div class="item-name">Early-Onset Alzheimer&#39;s Disease</div>
                
                <div class="item-desc">Type of Alzheimer&#39;s that occurs in individuals younger than 65 and is often associated with genetic factors.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30707186" target="_blank">PMID:30707186</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Early-onset Alzheimer disease (AD) is defined as having an age of onset younger than 65 years. ... Early-onset AD comprises about 5% to 6% of cases of AD and includes a substantial percentage of phenotypic variants that differ from the usual amnestic presentation of typical AD. Characteristics..."</div>
                
                
                <div class="evidence-explanation">This reference clearly supports the definition of Early-Onset Alzheimer&#39;s Disease as occurring in individuals younger than 65 and being often associated with genetic factors.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/25998117" target="_blank">PMID:25998117</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Young-onset dementia is hereditary, multifactorial, or sporadic. The most common hereditary dementias include Alzheimer disease."</div>
                
                
                <div class="evidence-explanation">This reference supports the idea that early-onset Alzheimer&#39;s disease can be hereditary, aligning with the statement&#39;s mention of genetic factors.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box subtype-box">
                <div class="item-name">Late-Onset Alzheimer&#39;s Disease</div>
                
                <div class="item-desc">The most common form of Alzheimer&#39;s, occurring in those aged 65 and older.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24429902" target="_blank">PMID:24429902</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In both cases, the disease results in severe cognitive dysfunction, among other problems, and the late-onset form of the disease is now considered to be the most common cause of dementia among the elderly."</div>
                
                
                <div class="evidence-explanation">The literature confirms that late-onset Alzheimer&#39;s Disease is the most common form of Alzheimer&#39;s and primarily affects those aged 65 and older.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34120901" target="_blank">PMID:34120901</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"BACKGROUND: Young onset dementia is associated with a longer time to diagnosis compared to late onset dementia."</div>
                
                
                <div class="evidence-explanation">The study differentiates between young onset and late onset Alzheimer&#39;s Disease, with late onset typically affecting older adults.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/18667359" target="_blank">PMID:18667359</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Alzheimer&#39;s disease accounts for 60% whereas vascular dementia accounts for approximately 30% of the prevalence. Early-onset familial forms of dementia with single-gene defects occur in Latin America, Asia, and Africa."</div>
                
                
                <div class="evidence-explanation">The literature indicates that late-onset Alzheimer&#39;s Disease is more prevalent compared to early-onset forms.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Pathophysiology -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">⚙</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">7</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Amyloid Plaque Formation</div>
                
                <div class="item-desc">Accumulation of amyloid-beta proteins in the brain, forming extracellular plaques that disrupt cell function and communication between neurons.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Neurons
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000540" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        Microglia
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000129" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        Astrocytes
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000127" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        Protein misfolding
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006457" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ⚠ ABNORMAL
    </span>
    
    
                    
                    <span class="tag tag-bio">
                        Aggregation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0034205" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        Neuroinflammation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0150076" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (8 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28320296" target="_blank">PMID:28320296</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"These intra- or extracellular insoluble aggregates (fibers or plaques) are hallmarks of many neurodegenerative pathologies including Alzheimer&#39;s disease (AD)..."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement by confirming that amyloid plaques are a hallmark of Alzheimer&#39;s disease and discusses the formation and role of amyloid aggregates in AD.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26322584" target="_blank">PMID:26322584</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Alzheimer disease (AD) is characterized by the accumulation of amyloid plaques, which are predominantly composed of amyloid-beta peptide."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement by indicating that the accumulation of amyloid plaques, composed of amyloid-beta peptide, is a characteristic of Alzheimer&#39;s disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22351073" target="_blank">PMID:22351073</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Generation of amyloid peptide (Abeta) is at the beginning of a cascade that leads to Alzheimer&#39;s disease (AD)... soluble assembly states of Abeta peptides can cause cognitive problems by disrupting synaptic function..."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement by mentioning that amyloid-beta peptides lead to Alzheimer&#39;s disease and cause synaptic dysfunction.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 5 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Neurofibrillary Tangle Formation</div>
                
                <div class="item-desc">Intracellular accumulation of hyperphosphorylated tau protein, forming twisted fibers that disrupt cellular transport and eventually lead to neuronal death.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Neurons
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000540" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        Protein hyperphosphorylation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006468" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ↑ INCREASED
    </span>
    
    
                    
                    <span class="tag tag-bio">
                        Microtubule destabilization
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0007019" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (9 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/21509508" target="_blank">PMID:21509508</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Extracellular accumulations of Abeta, hyperphosphorylation of tau and intracellular neurofibrillary tangle formation have been the hallmarks of Alzheimer&#39;s Disease (AD)."</div>
                
                
                <div class="evidence-explanation">The article discusses the role of tau hyperphosphorylation and neurofibrillary tangle formation in Alzheimer&#39;s Disease, supporting the statement about these processes.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36001963" target="_blank">PMID:36001963</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In Alzheimer&#39;s disease and other neurodegenerative tauopathies, tau is found hyperphosphorylated and aggregated in neurofibrillary tangles."</div>
                
                
                <div class="evidence-explanation">This article supports the statement by mentioning the hyperphosphorylation and aggregation of tau in neurofibrillary tangles in Alzheimer&#39;s Disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37266762" target="_blank">PMID:37266762</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Tau is a microtubule-associated binding protein in the nervous system that is known for its role in stabilizing microtubules throughout the nerve cell. It accumulates as beta-sheet-rich aggregates and neurofibrillary tangles, leading to an array of different pathologies."</div>
                
                
                <div class="evidence-explanation">The article confirms that hyperphosphorylated tau leads to the formation of neurofibrillary tangles and disrupts microtubule stabilization, supporting the statement.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 6 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Synaptic Dysfunction</div>
                
                <div class="item-desc">Progressive loss of synapses and impaired neurotransmitter signaling, leading to disrupted neuronal communication and cognitive decline.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Neurons
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000540" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        Neurotransmitter release
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0007269" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ↓ DECREASED
    </span>
    
    
                    
                    <span class="tag tag-bio">
                        Synaptic plasticity
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0048167" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ↓ DECREASED
    </span>
    
    
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27662312" target="_blank">PMID:27662312</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Compelling evidence suggests that soluble amyloid-beta (Abeta) and hyperphosphorylated tau serve as toxins in the dysfunction of synaptic plasticity and aberrant neurotransmitter (NT) release at synapses consequently causing a cognitive decline in Alzheimer&#39;s disease (AD)."</div>
                
                
                <div class="evidence-explanation">The statement is supported by the reference which discusses the role of neurotransmitter release and synaptic plasticity in Alzheimer&#39;s Disease, leading to cognitive decline.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27163751" target="_blank">PMID:27163751</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The important role of the hippocampus in age-related cognitive decline and in vulnerability to disease processes such as Alzheimer&#39;s disease has prompted this review, which will focus on the complexity of changes that characterize aging, and on the molecular connections that exist between normal..."</div>
                
                
                <div class="evidence-explanation">The reference supports the cognitive decline aspect but does not elaborate on neurotransmitter signaling or synaptic plasticity in detail.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/12973746" target="_blank">PMID:12973746</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Histological studies indicate loss of pyramidal neurones and their synapses in Alzheimer&#39;s disease (AD), this together with biochemical evidence suggests presynaptic (and postsynaptic) glutamatergic hypoactivity."</div>
                
                
                <div class="evidence-explanation">The reference supports the statement by discussing the loss of synapses and impaired glutamatergic neurotransmitter signaling in Alzheimer&#39;s Disease.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Neuroinflammation</div>
                
                <div class="item-desc">Chronic activation of immune responses in the brain, contributing to neuronal damage and disease progression.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Microglia
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000129" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        Astrocytes
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000127" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        Immune activation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0002253" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ↑ INCREASED
    </span>
    
    
                    
                    <span class="tag tag-bio">
                        Cytokine production
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0001816" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ↑ INCREASED
    </span>
    
    
                    
                    <span class="tag tag-bio">
                        Phagocytosis
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006909" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (6 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28019679" target="_blank">PMID:28019679</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"NOD-like receptor (NLR) family, pyrin domain containing 3 and 1 inflammasomes, present in myeloid cells and neurons, respectively, represent key components of the innate immune reaction observed in Alzheimer patient brains."</div>
                
                
                <div class="evidence-explanation">The reference supports the involvement of NLRP3 inflammasome activation in Alzheimer&#39;s disease, which is part of the immune activation process contributing to neuroinflammation.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32061803" target="_blank">PMID:32061803</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The response of astrocytes to the presence of Abeta, as well astrocytic and microglial interaction and inflammatory cytokine release is also discussed, highlighting a cyclical behaviour of these cells in contributing to AD pathogenesis."</div>
                
                
                <div class="evidence-explanation">This reference supports the role of astrocytes and microglia in cytokine production and their interaction contributing to Alzheimer&#39;s disease pathology.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35406803" target="_blank">PMID:35406803</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Once activated, microglial cells, which are brain-resident immune cells, exert several key actions, including phagocytosis, chemotaxis, and the release of pro- or anti-inflammatory mediators."</div>
                
                
                <div class="evidence-explanation">This reference supports the involvement of microglia in immune activation, cytokine production, and phagocytosis in Alzheimer&#39;s disease.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 3 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Oxidative Stress</div>
                
                <div class="item-desc">Imbalance between the production of reactive oxygen species and the brain&#39;s ability to detoxify them, leading to cellular damage.</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        Free radical production
                        
                        <a href="http://purl.obolibrary.org/obo/GO_1903409" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ↑ INCREASED
    </span>
    
    
                    
                    <span class="tag tag-bio">
                        Antioxidant defense
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006979" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ↓ DECREASED
    </span>
    
    
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34416493" target="_blank">PMID:34416493</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Emerging evidence suggests that accumulated oxidative stress may be one of the key mechanisms causing cognitive aging and neurodegenerative diseases such as Alzheimer&#39;s disease (AD)."</div>
                
                
                <div class="evidence-explanation">The literature supports the role of oxidative stress, including the imbalance between ROS production and antioxidant defenses, in the development of Alzheimer&#39;s disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27888001" target="_blank">PMID:27888001</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Depending on its level, HNE exerts harmful or protective effects associated with the induction of antioxidant defense mechanisms. These effects make HNE a key player in maintaining redox homeostasis, as well as producing imbalances in this system that participate in aging and the development of..."</div>
                
                
                <div class="evidence-explanation">This reference supports the involvement of oxidative stress and the imbalance in ROS/RNS in the pathology of neurodegenerative diseases.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/9024330" target="_blank">PMID:9024330</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Although the specific process that destroys neurons in patients with Alzheimer&#39;s disease (AD) remains obscure, biochemical studies of AD neurohistologic lesions and molecular attempts to map and clone genes in familial AD have contributed greatly to our knowledge of AD."</div>
                
                
                <div class="evidence-explanation">This reference discusses the uncertainty around the specific processes but acknowledges oxidative stress as a contributing factor.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Vascular Dysfunction</div>
                
                <div class="item-desc">Alterations in cerebral blood flow and blood-brain barrier integrity, contributing to neuronal dysfunction and amyloid accumulation.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Endothelial cells
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000115" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        Pericytes
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000669" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        Blood-brain barrier regulation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_1905603" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ↕ DYSREGULATED
    </span>
    
    
                    
                    <span class="tag tag-bio">
                        Cerebral blood flow
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0120275" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ↓ DECREASED
    </span>
    
    
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28902142" target="_blank">PMID:28902142</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Thus, current evidence suggests that BBB dysfunction may causatively and consequently contribute to AD pathogenesis, forming a vicious cycle between brain Abeta accumulation and neurovascular unit impairments during disease progression."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement by indicating that blood-brain barrier (BBB) dysfunction contributes to Alzheimer&#39;s disease (AD) pathogenesis, including amyloid-beta (Abeta) accumulation and neurovascular impairments.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/16443487" target="_blank">PMID:16443487</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Understanding cerebral degeneration and accumulation of beta-amyloid has generated hopes for discovery of disease-modifying treatments. Progress is needed in understanding the mechanisms that link beta-amyloid accumulation and neuronal death."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement by discussing the accumulation of beta-amyloid and its link to neuronal death in Alzheimer&#39;s disease, which is relevant to the described consequences of vascular dysfunction.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26898552" target="_blank">PMID:26898552</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"There is accumulating evidence suggesting that changes in brain perfusion are present long before the clinical symptoms of Alzheimer&#39;s disease (AD), perhaps even before amyloid-beta accumulation or brain atrophy."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement by highlighting the role of cerebral blood flow changes in the early stages of Alzheimer&#39;s disease, which is consistent with the described vascular dysfunction.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Autophagy-Lysosomal Dysfunction</div>
                
                <div class="item-desc">Impaired autophagy and lysosomal degradation pathways leading to accumulation of protein aggregates and cellular dysfunction.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Neurons
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000540" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        Autophagy
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006914" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ↓ DECREASED
    </span>
    
    
                    
                    <span class="tag tag-bio">
                        Lysosomal degradation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0007041" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ↓ DECREASED
    </span>
    
    
                    
                    <span class="tag tag-bio">
                        Protein catabolic process
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0030163" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ↓ DECREASED
    </span>
    
    
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        

        <!-- Causal Graph -->
        

        <!-- Phenotypes -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">●</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">6</span>
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Memory Loss
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Cognitive</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0002354" target="_blank">
                            HP:0002354
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">The earliest and most prominent symptom.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31724515" target="_blank">PMID:31724515</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Memory impairment has been considered as one of the earliest clinical hallmarks of Alzheimer&#39;s disease."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement that memory loss is a very frequent and early diagnostic symptom of Alzheimer&#39;s disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Executive Dysfunction
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Cognitive</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0100543" target="_blank">
                            HP:0100543
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Difficulty in planning, decision-making, and judgment.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24011643" target="_blank">PMID:24011643</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Impairment of executive functions is common in neurodegenerative disorders such as Alzheimer&#39;s disease."</div>
                
                
                <div class="evidence-explanation">The literature states that executive dysfunction, which includes difficulties in planning, decision-making, and judgment, is common in Alzheimer&#39;s disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31930617" target="_blank">PMID:31930617</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Alzheimer&#39;s disease (AD) is a neurodegenerative disease characterised by neurocognitive impairments, especially memory impairment, as core symptoms linked to reductions in activities of daily life."</div>
                
                
                <div class="evidence-explanation">The literature mentions neurocognitive impairments in Alzheimer&#39;s disease, which includes executive dysfunction.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36279224" target="_blank">PMID:36279224</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The cognitive decline in cerebrovascular disease, including small vessel disease, is also usually gradual and gradual, progresses slowly, and the underlying defect extends to processing speed, complex attention, and fronto-executive functions."</div>
                
                
                <div class="evidence-explanation">This reference indicates that executive dysfunction is a common feature in cognitive decline related to Alzheimer&#39;s disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Behavioral Changes
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Psychiatric</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0000708" target="_blank">
                            HP:0000708
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Includes irritability, depression, and apathy.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38157881" target="_blank">PMID:38157881</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Neuropsychiatric or behavioral symptoms of dementia encompass a series of disorders, such as anxiety, depression, apathy, psychosis, and agitation, all commonly present in individuals living with dementia."</div>
                
                
                <div class="evidence-explanation">The abstract confirms that behavioral changes, including irritability, depression, and apathy, are common in Alzheimer&#39;s disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28413709" target="_blank">PMID:28413709</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Using the median split approach, greater apathy and lower depression were associated with poorer awareness on the Self-Consciousness Scale (respectively: odds ratio ... = 4.8, p = .03; OR = 4.84, p = .04), and the PCRS (only apathy: OR = 9.3, p = .003)."</div>
                
                
                <div class="evidence-explanation">This study indicates that apathy and depression are significant behavioral symptoms in Alzheimer&#39;s disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34580191" target="_blank">PMID:34580191</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Alzheimer Disease and Mood."</div>
                
                
                <div class="evidence-explanation">The title suggests a focus on mood disturbances, which includes behavioral changes such as depression.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Aphasia
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurologic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0002381" target="_blank">
                            HP:0002381
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Difficulty with speech and understanding language.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24035593" target="_blank">PMID:24035593</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Language disorders of degenerative origin are frequently tied to Alzheimer disease (AD) the different variants of which can result in primary and secondary aphasia syndromes."</div>
                
                
                <div class="evidence-explanation">The literature clearly supports that aphasia, which involves difficulty with speech and understanding language, is a frequent neurologic symptom in Alzheimer&#39;s Disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Apraxia
                    
                    <span class="phenotype-freq">OCCASIONAL</span>
                    
                    
                    <span class="phenotype-category">Neurologic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0002186" target="_blank">
                            HP:0002186
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Difficulty with motor tasks despite intact motor function.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36375032" target="_blank">PMID:36375032</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Limb apraxia is a common early sign of Alzheimer&#39;&#39;s disease (AD) and is thought to occur specifically in early-onset (before the age of 65) AD."</div>
                
                
                <div class="evidence-explanation">The literature indicates that limb apraxia is a common early sign of Alzheimer&#39;s disease, supporting the statement that apraxia can occur in Alzheimer&#39;s disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Agnosia
                    
                    <span class="phenotype-freq">OCCASIONAL</span>
                    
                    
                    <span class="phenotype-category">Neurologic</span>
                    
                    
                </div>
                
                <div class="item-desc">Inability to recognize objects or people.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31930617" target="_blank">PMID:31930617</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Alzheimer&#39;s disease (AD) is a neurodegenerative disease characterised by neurocognitive impairments, especially memory impairment, as core symptoms linked to reductions in activities of daily life."</div>
                
                
                <div class="evidence-explanation">The provided literature discusses various neurocognitive impairments in Alzheimer&#39;s disease, but does not specifically mention agnosia.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29672553" target="_blank">PMID:29672553</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Faces are among the most relevant social stimuli revealing an encounter&#39;s identity and actual emotional state. Deficits in facial recognition may be an early sign of cognitive decline leading to social deficits."</div>
                
                
                <div class="evidence-explanation">The literature discusses deficits in facial recognition in patients with amnestic mild cognitive impairment, but does not explicitly mention agnosia in the context of Alzheimer&#39;s disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">🧬</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">8</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    APP
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Genetic Mutation)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (6 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/1365885" target="_blank">PMID:1365885</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Four mutations involving amino acid substitutions in exons 16 and 17 of the amyloid precursor protein (APP) gene, have been identified which co-segregate with the disease in some families multiply affected by early onset Alzheimer&#39;s disease."</div>
                
                
                <div class="evidence-explanation">This reference supports the association of APP genetic mutations with early-onset Alzheimer&#39;s disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33789815" target="_blank">PMID:33789815</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"This is the first case demonstrating that a low-degree APP gene-dose increase suffices to cause EOAD with prominent amyloid-beta/tau pathology."</div>
                
                
                <div class="evidence-explanation">This reference supports the role of APP gene mutations in causing early-onset Alzheimer&#39;s disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36306459" target="_blank">PMID:36306459</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Numerous mutations in amyloid precursor protein (APP) and presenilin 1 and 2 (PSEN1 and PSEN2) have been identified for EOAD, but they can only account for a small proportion of EOAD cases."</div>
                
                
                <div class="evidence-explanation">This reference supports the association of APP genetic mutations with early-onset Alzheimer&#39;s disease.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 3 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    PSEN1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Genetic Mutation)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (6 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31296348" target="_blank">PMID:31296348</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Presenilin 1 (PSEN1) gene mutations are the major known genetic cause of early-onset Alzheimer&#39;s disease."</div>
                
                
                <div class="evidence-explanation">The study reports a novel PSEN1 mutation associated with early-onset Alzheimer&#39;s disease, supporting the genetic association.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35487021" target="_blank">PMID:35487021</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"At present, three early-onset AD genes (APP, PSEN1, PSEN2) and one late-onset AD susceptibility gene apolipoprotein E (APOE) have been determined."</div>
                
                
                <div class="evidence-explanation">The reference confirms that PSEN1 is one of the genes associated with early-onset Alzheimer&#39;s disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36951251" target="_blank">PMID:36951251</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"A genetic association study was conducted to examine ADAD AAO in 340 individuals with the PSEN1 E280A mutation."</div>
                
                
                <div class="evidence-explanation">The study discusses a large cohort with a specific PSEN1 mutation associated with early-onset Alzheimer&#39;s disease, reinforcing the genetic link.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 3 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    PSEN2
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Genetic Mutation)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35491795" target="_blank">PMID:35491795</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The established causative mutations in the APP, PSEN1, and PSEN2 can explain less than 1%, Alzheimer&#39;&#39;s disease (AD) patients. Of the identified variants, the PSEN2 mutations are even less common."</div>
                
                
                <div class="evidence-explanation">The reference confirms that PSEN2 mutations are among the causative factors for early-onset Alzheimer&#39;s disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36701017" target="_blank">PMID:36701017</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Early-onset AD (EOAD) was defined as AD occurring before age 65. Although it has a high genetic risk, EOAD due to PSEN2 variation is very rare."</div>
                
                
                <div class="evidence-explanation">The reference supports the association of PSEN2 with early-onset Alzheimer&#39;s disease, although it notes that such cases are rare.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32741831" target="_blank">PMID:32741831</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Early-onset familial Alzheimer disease (EOFAD) is caused by heterozygous variants in the presenilin 1 (PSEN1), presenilin 2 (PSEN2), and APP genes."</div>
                
                
                <div class="evidence-explanation">The reference explicitly states that early-onset familial Alzheimer&#39;s disease can be caused by PSEN2 mutations.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    APOE
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Risk Factor)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    TREM2
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Risk Factor)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    NLRP3
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Genetic Variant)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    PYCARD
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Genetic Variant)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    LRP1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Genetic Variant)</span>
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">💊</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">5</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Cholinesterase Inhibitors
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Medications that slow the breakdown of acetylcholine to help with memory and cognitive function (e.g., donepezil, rivastigmine).</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24807367" target="_blank">PMID:24807367</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Donepezil, galantamine and rivastigmine are commonly used AChEIs in pharmacotherapy for AD, slowing the progression and controlling the symptoms of AD."</div>
                
                
                <div class="evidence-explanation">The literature supports that cholinesterase inhibitors, including donepezil and rivastigmine, are used to help with symptoms of Alzheimer&#39;s disease by slowing the progression and controlling cognitive symptoms.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28671413" target="_blank">PMID:28671413</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Cholinesterase inhibitors, memantine, and a combination of a cholinesterase inhibitor and memantine have produced statistically significant but clinically small delays in various domains of cognitive and functional decline in select patients with Alzheimer disease."</div>
                
                
                <div class="evidence-explanation">The literature supports the use of cholinesterase inhibitors in delaying cognitive decline in Alzheimer&#39;s disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35608903" target="_blank">PMID:35608903</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Two classes of drug - cholinesterase inhibitors (donepezil, galantamine and rivastigmine) and memantine - are widely licensed for dementia due to Alzheimer&#39;&#39;s disease."</div>
                
                
                <div class="evidence-explanation">The literature confirms that cholinesterase inhibitors are licensed for use in Alzheimer&#39;s disease to alleviate symptoms and delay disease progression.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    NMDA Receptor Antagonist
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Medication that regulates glutamate activity to improve symptoms (e.g., memantine).</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/12768511" target="_blank">PMID:12768511</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Memantine, an antagonist of the glutamatergic NMDA receptor, has been recently approved for the treatment of advanced AD. Due to its action mechanism, memantine is considered a neuroprotective drug, whose utility has been demonstrated in preclinical studies, and a useful symptomatic treatment..."</div>
                
                
                <div class="evidence-explanation">The abstract confirms that memantine, an NMDA receptor antagonist, is used to treat Alzheimer&#39;s Disease by regulating glutamate activity.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27662322" target="_blank">PMID:27662322</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Studies indicate that the distinct outcomes of NMDAR-mediated responses are induced by regionalized receptor activities, followed by different downstream signaling pathways. The activation of synaptic NMDARs initiates plasticity and stimulates cell survival. In contrast, the activation of..."</div>
                
                
                <div class="evidence-explanation">This abstract highlights that memantine, an NMDA receptor antagonist, helps in blocking the negative effects of excessive NMDAR activity in Alzheimer&#39;s Disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/20943326" target="_blank">PMID:20943326</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The hypothesis proposed is restoration of medium spiny neurons in Huntington&#39;s disease using neural progenitor cell implantation and attenuation of glutamate mediated excitotoxicity using a partial glutamate antagonist - Memantine. Memantine can block the NMDA receptors and will prevent excess..."</div>
                
                
                <div class="evidence-explanation">Although primarily discussing Huntington&#39;s Disease, this abstract supports the idea that memantine, an NMDA receptor antagonist, regulates glutamate activity, which is relevant to Alzheimer&#39;s Disease treatment.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Cognitive Therapy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000077" target="_blank">
                            MAXO:0000077
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Non-pharmacological interventions to maintain cognitive function.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35621327" target="_blank">PMID:35621327</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Cognitive stimulation was found to be an effective intervention for people with moderate Alzheimer&#39;s disease because it helped to maintain memory function, executive functions, and attention."</div>
                
                
                <div class="evidence-explanation">This study specifically highlights the effectiveness of cognitive stimulation in maintaining cognitive functions in patients with moderate Alzheimer&#39;s disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28671413" target="_blank">PMID:28671413</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Cognitive stimulation programs show benefit in maintenance of cognitive function and improved self-reported quality of life in patients with mild to moderate Alzheimer disease."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement by indicating that cognitive stimulation programs help maintain cognitive function in patients with mild to moderate Alzheimer&#39;s disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37428401" target="_blank">PMID:37428401</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"CS confers temporary, nonspecific benefits and might slightly reduce dementia risk for neurologically healthy individuals."</div>
                
                
                <div class="evidence-explanation">This reference indicates that cognitive stimulation offers temporary benefits and might reduce dementia risk, but it is less clear about long-term maintenance of cognitive function specifically in Alzheimer&#39;s disease.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Supportive Care
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000950" target="_blank">
                            MAXO:0000950
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Includes occupational therapy, speech therapy, and caregiver support.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28809650" target="_blank">PMID:28809650</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Occupational therapy practitioners play a significant role in supporting adults with Alzheimer&#39;s disease and related major neurocognitive disorders, as well as their caregivers, through all phases of the disease process."</div>
                
                
                <div class="evidence-explanation">The reference highlights the role of occupational therapy in supporting individuals with Alzheimer&#39;s disease, which aligns with the statement that includes occupational therapy as part of supportive care.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38883339" target="_blank">PMID:38883339</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The telephone hotline is a useful component of dementia care in Germany and an important contribution to the National Dementia Strategy."</div>
                
                
                <div class="evidence-explanation">The reference discusses the importance of caregiver support through telephone counseling, aligning with the statement that includes caregiver support as part of supportive care.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29361068" target="_blank">PMID:29361068</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"This article first describes the educational, information, and support needs of individuals living dementia and their family caregivers across all stages of Alzheimer&#39;s."</div>
                
                
                <div class="evidence-explanation">The reference discusses the support needs of individuals with Alzheimer&#39;s disease and their caregivers, which aligns with the statement that includes caregiver support as part of supportive care.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Lifestyle Modifications
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000088" target="_blank">
                            MAXO:0000088
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Physical exercise, mental stimulation, and healthy diet to potentially slow disease progression.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35503939" target="_blank">PMID:35503939</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The aim of this review is to emphasize the importance of mental activity and aerobic physical exercise as one of the most important health-related activities which may delay the onset or slow down the progression of Alzheimer&#39;s dementia."</div>
                
                
                <div class="evidence-explanation">The review highlights the importance of mental and physical exercise in potentially slowing the progression of Alzheimer&#39;s disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32579499" target="_blank">PMID:32579499</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Combined with the prevention of AD risk factors such as heart disease, diabetes, and with more recent evidence, microbiome dysfunction, there is a substantial foundation for diet as a modifiable risk factor and preventative measure for AD."</div>
                
                
                <div class="evidence-explanation">The review suggests that a healthy diet can be a preventative measure for Alzheimer&#39;s disease, supporting the role of lifestyle modifications.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37321363" target="_blank">PMID:37321363</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Results showed that eating a healthy diet with plenty of fruits and vegetables, and participation in leisure and physical activities may protect against cognitive decline and cognitive impairment among oldest-old regardless of the APOE genotype."</div>
                
                
                <div class="evidence-explanation">The systematic review indicates that lifestyle factors such as diet and physical activities may protect against cognitive decline, supporting the statement.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">🔬</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Amyloid Beta (Aβ42)
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Elevated)</span>
                    
                </div>
                
                <div class="item-desc">Context: Found in cerebrospinal fluid and brain tissue.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/19661632" target="_blank">PMID:19661632</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The core candidate CSF biomarkers Abeta42, total tau (T-tau), and phosphorylated tau (P-tau) have been shown to have a high diagnostic performance to identify AD also in the early phase of the disease."</div>
                
                
                <div class="evidence-explanation">The literature confirms that Abeta42 is a core biomarker found in cerebrospinal fluid (CSF) and is elevated in Alzheimer&#39;s disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31958088" target="_blank">PMID:31958088</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Genetic predispositions associated with metabolism of the amyloid-beta protein precursor underlie familial Alzheimer&#39;s disease; a form of dementia characterized by early disease onset and elevated levels of cortical amyloid-beta."</div>
                
                
                <div class="evidence-explanation">The literature confirms that elevated levels of amyloid-beta, including Abeta42, are found in the brain tissue of individuals with Alzheimer&#39;s disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38987603" target="_blank">PMID:38987603</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"beta-amyloid plaques contained a mixture of fibrils, some of which were branched, and protofilaments, arranged in parallel arrays and lattice-like structures."</div>
                
                
                <div class="evidence-explanation">This reference supports the presence of beta-amyloid in brain tissue, which includes Abeta42, in Alzheimer&#39;s disease.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Alhzeimer_Disease
disease_term:
  preferred_term: Alzheimer disease
  term:
    id: MONDO:0004975
    label: Alzheimer disease
category: Neurodegenerative Disorder
parents:
- Dementia
has_subtypes:
- name: Early-Onset Alzheimer&#39;s Disease
  description: Type of Alzheimer&#39;s that occurs in individuals younger than 65 and
    is often associated with genetic factors.
  evidence:
  - reference: PMID:30707186
    supports: SUPPORT
    snippet: Early-onset Alzheimer disease (AD) is defined as having an age of onset
      younger than 65 years. ... Early-onset AD comprises about 5% to 6% of cases
      of AD and includes a substantial percentage of phenotypic variants that differ
      from the usual amnestic presentation of typical AD. Characteristics of early-onset
      AD in comparison to late-onset AD include a larger genetic predisposition (familial
      mutations and summed polygenic risk)
    explanation: This reference clearly supports the definition of Early-Onset Alzheimer&#39;s
      Disease as occurring in individuals younger than 65 and being often associated
      with genetic factors.
  - reference: PMID:25998117
    supports: SUPPORT
    snippet: Young-onset dementia is hereditary, multifactorial, or sporadic. The
      most common hereditary dementias include Alzheimer disease.
    explanation: This reference supports the idea that early-onset Alzheimer&#39;s disease
      can be hereditary, aligning with the statement&#39;s mention of genetic factors.
- name: Late-Onset Alzheimer&#39;s Disease
  description: The most common form of Alzheimer&#39;s, occurring in those aged 65 and
    older.
  evidence:
  - reference: PMID:24429902
    supports: SUPPORT
    snippet: In both cases, the disease results in severe cognitive dysfunction, among
      other problems, and the late-onset form of the disease is now considered to
      be the most common cause of dementia among the elderly.
    explanation: The literature confirms that late-onset Alzheimer&#39;s Disease is the
      most common form of Alzheimer&#39;s and primarily affects those aged 65 and older.
  - reference: PMID:34120901
    supports: SUPPORT
    snippet: &#39;BACKGROUND: Young onset dementia is associated with a longer time to
      diagnosis compared to late onset dementia.&#39;
    explanation: The study differentiates between young onset and late onset Alzheimer&#39;s
      Disease, with late onset typically affecting older adults.
  - reference: PMID:18667359
    supports: SUPPORT
    snippet: Alzheimer&#39;s disease accounts for 60% whereas vascular dementia accounts
      for approximately 30% of the prevalence. Early-onset familial forms of dementia
      with single-gene defects occur in Latin America, Asia, and Africa.
    explanation: The literature indicates that late-onset Alzheimer&#39;s Disease is more
      prevalent compared to early-onset forms.
prevalence:
- population: Global
  percentage: 5.8
  evidence:
  - reference: PMID:23159715
    supports: NO_EVIDENCE
    snippet: It was estimated that in 2010 there were 36.5 million people living with
      dementia, with 7.7 million new cases yearly and a new case of dementia every
      4 sec.
    explanation: The literature provides global prevalence data for dementia but does
      not specify a percentage of 5.8% for Alzheimer&#39;s disease.
  - reference: PMID:38008402
    supports: NO_EVIDENCE
    snippet: According to the facts and figures 2023stated that 6.7 million Americans
      over the age of 65 have Alzheimer&#39;s disease (AD).
    explanation: The literature provides the number of Americans with Alzheimer&#39;s
      disease but does not specify a global percentage of 5.8%.
pathophysiology:
- name: Amyloid Plaque Formation
  description: Accumulation of amyloid-beta proteins in the brain, forming extracellular
    plaques that disrupt cell function and communication between neurons.
  cell_types:
  - preferred_term: Neurons
    term:
      id: CL:0000540
      label: neuron
  - preferred_term: Microglia
    term:
      id: CL:0000129
      label: microglial cell
  - preferred_term: Astrocytes
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: Protein misfolding
    modifier: ABNORMAL
    term:
      id: GO:0006457
      label: protein folding
  - preferred_term: Aggregation
    term:
      id: GO:0034205
      label: amyloid-beta formation
  - preferred_term: Neuroinflammation
    term:
      id: GO:0150076
      label: neuroinflammatory response
  locations:
  - preferred_term: Cerebral Cortex
  - preferred_term: Hippocampus
  - preferred_term: Subcortical Regions
  chemical_entities:
  - preferred_term: Amyloid-beta peptides (Aβ40, Aβ42)
  genes:
  - preferred_term: APP
    term:
      id: HGNC:620
      label: APP
  - preferred_term: PSEN1
    term:
      id: HGNC:9508
      label: PSEN1
  - preferred_term: PSEN2
    term:
      id: HGNC:9509
      label: PSEN2
  pathways:
  - preferred_term: Amyloid precursor protein processing
    term:
      id: GO:0042982
      label: amyloid precursor protein metabolic process
  mechanisms:
  - Beta-secretase (BACE1) cleavage of APP
  - Gamma-secretase cleavage of APP C-terminal fragment
  consequences:
  - Synaptic Dysfunction
  - Neuroinflammation
  evidence:
  - reference: PMID:28320296
    supports: SUPPORT
    snippet: These intra- or extracellular insoluble aggregates (fibers or plaques)
      are hallmarks of many neurodegenerative pathologies including Alzheimer&#39;s disease
      (AD)...
    explanation: This reference supports the statement by confirming that amyloid
      plaques are a hallmark of Alzheimer&#39;s disease and discusses the formation and
      role of amyloid aggregates in AD.
  - reference: PMID:26322584
    supports: SUPPORT
    snippet: Alzheimer disease (AD) is characterized by the accumulation of amyloid
      plaques, which are predominantly composed of amyloid-beta peptide.
    explanation: This reference supports the statement by indicating that the accumulation
      of amyloid plaques, composed of amyloid-beta peptide, is a characteristic of
      Alzheimer&#39;s disease.
  - reference: PMID:22351073
    supports: SUPPORT
    snippet: Generation of amyloid peptide (Abeta) is at the beginning of a cascade
      that leads to Alzheimer&#39;s disease (AD)... soluble assembly states of Abeta peptides
      can cause cognitive problems by disrupting synaptic function...
    explanation: This reference supports the statement by mentioning that amyloid-beta
      peptides lead to Alzheimer&#39;s disease and cause synaptic dysfunction.
  - reference: PMID:10911965
    supports: SUPPORT
    snippet: Alzheimer&#39;s disease (AD) pathology is characterized by A beta peptide-containing
      plaques, neurofibrillary tangles consisting of hyperphosphorylated tau, extensive
      neuritic degeneration, and distinct neuron loss.
    explanation: This reference supports the statement by describing Alzheimer&#39;s disease
      pathology, including amyloid-beta peptide-containing plaques.
  - reference: PMID:10702374
    supports: SUPPORT
    snippet: beta-amyloid (Abeta) is the main constituent of the amyloidogenic plaques
      which are a primary pathological hallmark of Alzheimer&#39;s disease...
    explanation: This reference supports the statement by confirming that beta-amyloid
      is the main constituent of amyloid plaques, a hallmark of Alzheimer&#39;s disease.
  - reference: PMID:36555791
    supports: SUPPORT
    snippet: Neuritic plaques are one of the major pathological hallmarks of Alzheimer&#39;s
      disease. They are formed by the aggregation of extracellular amyloid-beta protein
      (Abeta)...
    explanation: This reference supports the statement by indicating that neuritic
      plaques, formed by the aggregation of amyloid-beta protein, are a hallmark of
      Alzheimer&#39;s disease.
  - reference: PMID:25941885
    supports: SUPPORT
    snippet: The &#39;amyloid cascade hypothesis&#39; posits that an extracellular build-up
      of amyloid-beta oligomers (Abeta-os) and polymers (fibrils) subsequently inducing
      toxic hyperphosphorylated (p)-Tau oligomers (p-Tau-os) and neurofibrillary tangles
      starts the sporadic late-onset Alzheimer&#39;s disease (LOAD)...
    explanation: This reference supports the statement by discussing the amyloid cascade
      hypothesis, which involves the build-up of amyloid-beta leading to Alzheimer&#39;s
      disease.
  - reference: PMID:16611586
    supports: SUPPORT
    snippet: The amyloidogenesis occurring in Alzheimer&#39;s disease represents a fundamental
      membrane-related pathology... the amyloid-beta peptide (Abeta), which accumulates
      extracellularly as plaques in the brains of Alzheimer&#39;s disease patients...
    explanation: This reference supports the statement by describing the accumulation
      of amyloid-beta peptide as plaques in Alzheimer&#39;s disease.
- name: Neurofibrillary Tangle Formation
  description: Intracellular accumulation of hyperphosphorylated tau protein, forming
    twisted fibers that disrupt cellular transport and eventually lead to neuronal
    death.
  cell_types:
  - preferred_term: Neurons
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: Protein hyperphosphorylation
    modifier: INCREASED
    term:
      id: GO:0006468
      label: protein phosphorylation
  - preferred_term: Microtubule destabilization
    term:
      id: GO:0007019
      label: microtubule depolymerization
  locations:
  - preferred_term: Entorhinal Cortex
  - preferred_term: Hippocampus
  - preferred_term: Neocortex
  chemical_entities:
  - preferred_term: Tau protein
  genes:
  - preferred_term: MAPT
    term:
      id: HGNC:6893
      label: MAPT
  pathways:
  - preferred_term: Tau phosphorylation cascade
    term:
      id: GO:0006468
      label: protein phosphorylation
  mechanisms:
  - Hyperphosphorylation of tau by various kinases
  - Aggregation of hyperphosphorylated tau
  consequence: Synaptic Dysfunction
  evidence:
  - reference: PMID:21509508
    supports: SUPPORT
    snippet: Extracellular accumulations of Abeta, hyperphosphorylation of tau and
      intracellular neurofibrillary tangle formation have been the hallmarks of Alzheimer&#39;s
      Disease (AD).
    explanation: The article discusses the role of tau hyperphosphorylation and neurofibrillary
      tangle formation in Alzheimer&#39;s Disease, supporting the statement about these
      processes.
  - reference: PMID:36001963
    supports: SUPPORT
    snippet: In Alzheimer&#39;s disease and other neurodegenerative tauopathies, tau is
      found hyperphosphorylated and aggregated in neurofibrillary tangles.
    explanation: This article supports the statement by mentioning the hyperphosphorylation
      and aggregation of tau in neurofibrillary tangles in Alzheimer&#39;s Disease.
  - reference: PMID:37266762
    supports: SUPPORT
    snippet: Tau is a microtubule-associated binding protein in the nervous system
      that is known for its role in stabilizing microtubules throughout the nerve
      cell. It accumulates as beta-sheet-rich aggregates and neurofibrillary tangles,
      leading to an array of different pathologies.
    explanation: The article confirms that hyperphosphorylated tau leads to the formation
      of neurofibrillary tangles and disrupts microtubule stabilization, supporting
      the statement.
  - reference: PMID:19542604
    supports: SUPPORT
    snippet: Tau protein is the principal component of the neurofibrillary tangles
      found in Alzheimer&#39;s disease (AD), where it is hyperphosphorylated on serine
      and threonine residues.
    explanation: This article supports the statement by identifying hyperphosphorylated
      tau as the main component of neurofibrillary tangles in Alzheimer&#39;s Disease.
  - reference: PMID:28100644
    supports: SUPPORT
    snippet: These multicellular interactions are initiated by insoluble tangles of
      phosphorylated tau protein and plaques of amyloid peptides.
    explanation: This article supports the statement by discussing how phosphorylated
      tau protein tangles initiate multicellular interactions in Alzheimer&#39;s Disease.
  - reference: PMID:2135393
    supports: SUPPORT
    snippet: The most common of these conditions is Alzheimer&#39;s disease, in which
      microtubules are lost from neurites that fill up with filamentous structures.
      One component of the filamentous structures is the microtubule-associated protein
      (MAP), tau.
    explanation: The article supports the statement by explaining how tau protein
      is involved in the formation of filamentous structures in Alzheimer&#39;s Disease,
      leading to microtubule destabilization.
  - reference: PMID:12859672
    supports: SUPPORT
    snippet: Neurofibrillary tangles are composed of insoluble aggregates of the microtubule-associated
      protein tau. In Alzheimer&#39;s disease the accumulation of neurofibrillary tangles
      occurs in the absence of tau mutations.
    explanation: This article supports the statement by describing the composition
      and formation of neurofibrillary tangles from tau protein in Alzheimer&#39;s Disease.
  - reference: PMID:31903881
    supports: SUPPORT
    snippet: Hyperphosphorylation of tau protein leads to aggregation of tau into
      paired helical filaments like structures which are major constituents of neurofibrillary
      tangles, a hallmark of Alzheimer&#39;s disease.
    explanation: The article supports the statement by linking tau hyperphosphorylation
      and aggregation to the formation of neurofibrillary tangles in Alzheimer&#39;s Disease.
  - reference: PMID:23948895
    supports: SUPPORT
    snippet: Tauopathies are neurodegenerative diseases characterized behaviorally
      by dementia and neuropathologically by neurofibrillary tangles and neuronal
      loss.
    explanation: The article supports the statement by describing tauopathies, including
      Alzheimer&#39;s Disease, as being characterized by neurofibrillary tangles and neuronal
      loss.
- name: Synaptic Dysfunction
  description: Progressive loss of synapses and impaired neurotransmitter signaling,
    leading to disrupted neuronal communication and cognitive decline.
  cell_types:
  - preferred_term: Neurons
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: Neurotransmitter release
    modifier: DECREASED
    term:
      id: GO:0007269
      label: neurotransmitter secretion
  - preferred_term: Synaptic plasticity
    modifier: DECREASED
    term:
      id: GO:0048167
      label: regulation of synaptic plasticity
  locations:
  - preferred_term: Synapses
  - preferred_term: Neuronal dendrites
  chemical_entities:
  - preferred_term: Acetylcholine
    term:
      id: CHEBI:15355
      label: acetylcholine
  - preferred_term: Glutamate
    term:
      id: CHEBI:14321
      label: glutamate(1-)
  - preferred_term: GABA
    term:
      id: CHEBI:16865
      label: gamma-aminobutyric acid
  pathways:
  - preferred_term: Synaptic vesicle recycling
    term:
      id: GO:0099504
      label: synaptic vesicle cycle
  - preferred_term: Neurotransmitter receptor signaling
    term:
      id: GO:0050804
      label: modulation of chemical synaptic transmission
  consequence: Oxidative Stress
  evidence:
  - reference: PMID:27662312
    supports: SUPPORT
    snippet: Compelling evidence suggests that soluble amyloid-beta (Abeta) and hyperphosphorylated
      tau serve as toxins in the dysfunction of synaptic plasticity and aberrant neurotransmitter
      (NT) release at synapses consequently causing a cognitive decline in Alzheimer&#39;s
      disease (AD).
    explanation: The statement is supported by the reference which discusses the role
      of neurotransmitter release and synaptic plasticity in Alzheimer&#39;s Disease,
      leading to cognitive decline.
  - reference: PMID:27163751
    supports: PARTIAL
    snippet: The important role of the hippocampus in age-related cognitive decline
      and in vulnerability to disease processes such as Alzheimer&#39;s disease has prompted
      this review, which will focus on the complexity of changes that characterize
      aging, and on the molecular connections that exist between normal aging and
      Alzheimer&#39;s disease.
    explanation: The reference supports the cognitive decline aspect but does not
      elaborate on neurotransmitter signaling or synaptic plasticity in detail.
  - reference: PMID:12973746
    supports: SUPPORT
    snippet: Histological studies indicate loss of pyramidal neurones and their synapses
      in Alzheimer&#39;s disease (AD), this together with biochemical evidence suggests
      presynaptic (and postsynaptic) glutamatergic hypoactivity.
    explanation: The reference supports the statement by discussing the loss of synapses
      and impaired glutamatergic neurotransmitter signaling in Alzheimer&#39;s Disease.
  - reference: PMID:33232936
    supports: SUPPORT
    snippet: In the present study, we examined alterations in several GABA-specific
      targets in the APP/PS1 mouse model at different ages... Overall, our study provides
      evidence of altered GABAergic signaling in an amyloid model of AD at a time
      point consistent with AD-related deficits.
    explanation: The reference supports the statement by providing evidence of altered
      GABAergic signaling and its role in Alzheimer&#39;s Disease.
  - reference: PMID:9024330
    supports: SUPPORT
    snippet: The major component of the extraneuronal neuritic plaque is beta-amyloid
      (A beta), which may be neurotoxic. The major component of the intraneuronal
      neurofibrillary tangle is hyperphosphorylated tau protein.
    explanation: The reference supports the statement by discussing neurotoxic components
      that contribute to synaptic dysfunction and cognitive decline in Alzheimer&#39;s
      Disease.
- name: Neuroinflammation
  description: Chronic activation of immune responses in the brain, contributing to
    neuronal damage and disease progression.
  cell_types:
  - preferred_term: Microglia
    term:
      id: CL:0000129
      label: microglial cell
  - preferred_term: Astrocytes
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: Immune activation
    modifier: INCREASED
    term:
      id: GO:0002253
      label: activation of immune response
  - preferred_term: Cytokine production
    modifier: INCREASED
    term:
      id: GO:0001816
      label: cytokine production
  - preferred_term: Phagocytosis
    term:
      id: GO:0006909
      label: phagocytosis
  chemical_entities:
  - preferred_term: Cytokines
  - preferred_term: Chemokines
  - preferred_term: Complement proteins
  pathways:
  - preferred_term: NF-κB signaling
    term:
      id: GO:0007249
      label: canonical NF-kappaB signal transduction
  - preferred_term: NLRP3 inflammasome activation
    term:
      id: GO:0044546
      label: NLRP3 inflammasome complex assembly
  consequences:
  - Oxidative Stress
  - Vascular Dysfunction
  evidence:
  - reference: PMID:28019679
    supports: SUPPORT
    snippet: NOD-like receptor (NLR) family, pyrin domain containing 3 and 1 inflammasomes,
      present in myeloid cells and neurons, respectively, represent key components
      of the innate immune reaction observed in Alzheimer patient brains.
    explanation: The reference supports the involvement of NLRP3 inflammasome activation
      in Alzheimer&#39;s disease, which is part of the immune activation process contributing
      to neuroinflammation.
  - reference: PMID:32061803
    supports: SUPPORT
    snippet: The response of astrocytes to the presence of Abeta, as well astrocytic
      and microglial interaction and inflammatory cytokine release is also discussed,
      highlighting a cyclical behaviour of these cells in contributing to AD pathogenesis.
    explanation: This reference supports the role of astrocytes and microglia in cytokine
      production and their interaction contributing to Alzheimer&#39;s disease pathology.
  - reference: PMID:35406803
    supports: SUPPORT
    snippet: Once activated, microglial cells, which are brain-resident immune cells,
      exert several key actions, including phagocytosis, chemotaxis, and the release
      of pro- or anti-inflammatory mediators.
    explanation: This reference supports the involvement of microglia in immune activation,
      cytokine production, and phagocytosis in Alzheimer&#39;s disease.
  - reference: PMID:21546088
    supports: SUPPORT
    snippet: In age related diseases, such as Alzheimer&#39;s disease (AD), accumulating
      amyloid proteins elicit complement activation and a local, chronic inflammatory
      response that leads to attraction and activation of glial cells that, under
      such activation conditions, can produce neurotoxic substances, including pro-inflammatory
      cytokines and oxygen radicals.
    explanation: This reference supports the involvement of complement proteins, cytokines,
      and oxidative stress in Alzheimer&#39;s disease.
  - reference: PMID:33958577
    supports: SUPPORT
    snippet: The apoptotic loss of dendritic spines would be aggravated by microglia
      activation through a recently described signaling system from complement abnormalities
      and proteins of the MHC, thus implicating the immune system in schizophrenia.
    explanation: While primarily discussing schizophrenia, this reference supports
      the role of microglia activation and complement proteins in neuroinflammation,
      which is relevant to Alzheimer&#39;s disease.
  - reference: PMID:36357946
    supports: SUPPORT
    snippet: Furthermore, exposure to chronic stress alters the phenotype of microglia,
      a population of innate immune cells that reside in the CNS parenchyma.
    explanation: This reference supports the role of microglia as key players in immune
      activation and neuroinflammation.
- name: Oxidative Stress
  description: Imbalance between the production of reactive oxygen species and the
    brain&#39;s ability to detoxify them, leading to cellular damage.
  biological_processes:
  - preferred_term: Free radical production
    modifier: INCREASED
    term:
      id: GO:1903409
      label: reactive oxygen species biosynthetic process
  - preferred_term: Antioxidant defense
    modifier: DECREASED
    term:
      id: GO:0006979
      label: response to oxidative stress
  cellular_components:
  - preferred_term: Mitochondria
    term:
      id: GO:0005739
      label: mitochondrion
  - preferred_term: Cell membranes
    term:
      id: GO:0005886
      label: plasma membrane
  chemical_entities:
  - preferred_term: Reactive oxygen species (ROS)
    term:
      id: CHEBI:26523
      label: reactive oxygen species
  - preferred_term: Reactive nitrogen species (RNS)
    term:
      id: CHEBI:62764
      label: reactive nitrogen species
  pathways:
  - preferred_term: Mitochondrial electron transport chain
    term:
      id: GO:0022904
      label: respiratory electron transport chain
  - preferred_term: NADPH oxidase activation
  consequences:
  - Amyloid Plaque Formation
  - Neurofibrillary Tangle Formation
  evidence:
  - reference: PMID:34416493
    supports: SUPPORT
    snippet: Emerging evidence suggests that accumulated oxidative stress may be one
      of the key mechanisms causing cognitive aging and neurodegenerative diseases
      such as Alzheimer&#39;s disease (AD).
    explanation: The literature supports the role of oxidative stress, including the
      imbalance between ROS production and antioxidant defenses, in the development
      of Alzheimer&#39;s disease.
  - reference: PMID:27888001
    supports: SUPPORT
    snippet: Depending on its level, HNE exerts harmful or protective effects associated
      with the induction of antioxidant defense mechanisms. These effects make HNE
      a key player in maintaining redox homeostasis, as well as producing imbalances
      in this system that participate in aging and the development of pathological
      conditions.
    explanation: This reference supports the involvement of oxidative stress and the
      imbalance in ROS/RNS in the pathology of neurodegenerative diseases.
  - reference: PMID:9024330
    supports: PARTIAL
    snippet: Although the specific process that destroys neurons in patients with
      Alzheimer&#39;s disease (AD) remains obscure, biochemical studies of AD neurohistologic
      lesions and molecular attempts to map and clone genes in familial AD have contributed
      greatly to our knowledge of AD.
    explanation: This reference discusses the uncertainty around the specific processes
      but acknowledges oxidative stress as a contributing factor.
  - reference: PMID:25772897
    supports: PARTIAL
    snippet: Key elements driving neurodegeneration include microglia activation,
      chronic oxidative injury, accumulation of mitochondrial damage in axons, and
      age-related iron accumulation in the human brain.
    explanation: This reference supports the involvement of oxidative stress and mitochondrial
      damage in neurodegeneration but does not specifically focus on Alzheimer&#39;s disease.
  - reference: PMID:33164705
    supports: SUPPORT
    snippet: Oxidative stress-induced neuronal apoptosis plays a pivotal role in pathogenesis
      of neurodegeneration.
    explanation: This reference supports the role of oxidative stress in neurodegeneration,
      which is relevant to Alzheimer&#39;s disease.
- name: Vascular Dysfunction
  description: Alterations in cerebral blood flow and blood-brain barrier integrity,
    contributing to neuronal dysfunction and amyloid accumulation.
  cell_types:
  - preferred_term: Endothelial cells
    term:
      id: CL:0000115
      label: endothelial cell
  - preferred_term: Pericytes
    term:
      id: CL:0000669
      label: pericyte
  biological_processes:
  - preferred_term: Blood-brain barrier regulation
    modifier: DYSREGULATED
    term:
      id: GO:1905603
      label: regulation of blood-brain barrier permeability
  - preferred_term: Cerebral blood flow
    modifier: DECREASED
    term:
      id: GO:0120275
      label: cerebral blood circulation
  locations:
  - preferred_term: Cerebral blood vessels
  - preferred_term: Blood-brain barrier
  pathways:
  - preferred_term: Neurovascular coupling
  - preferred_term: Perivascular drainage
  genes:
  - preferred_term: LRP1
    term:
      id: HGNC:6692
      label: LRP1
  consequences:
  - Amyloid Plaque Formation
  - Oxidative Stress
  evidence:
  - reference: PMID:28902142
    supports: SUPPORT
    snippet: Thus, current evidence suggests that BBB dysfunction may causatively
      and consequently contribute to AD pathogenesis, forming a vicious cycle between
      brain Abeta accumulation and neurovascular unit impairments during disease progression.
    explanation: This reference supports the statement by indicating that blood-brain
      barrier (BBB) dysfunction contributes to Alzheimer&#39;s disease (AD) pathogenesis,
      including amyloid-beta (Abeta) accumulation and neurovascular impairments.
  - reference: PMID:16443487
    supports: SUPPORT
    snippet: Understanding cerebral degeneration and accumulation of beta-amyloid
      has generated hopes for discovery of disease-modifying treatments. Progress
      is needed in understanding the mechanisms that link beta-amyloid accumulation
      and neuronal death.
    explanation: This reference supports the statement by discussing the accumulation
      of beta-amyloid and its link to neuronal death in Alzheimer&#39;s disease, which
      is relevant to the described consequences of vascular dysfunction.
  - reference: PMID:26898552
    supports: SUPPORT
    snippet: There is accumulating evidence suggesting that changes in brain perfusion
      are present long before the clinical symptoms of Alzheimer&#39;s disease (AD), perhaps
      even before amyloid-beta accumulation or brain atrophy.
    explanation: This reference supports the statement by highlighting the role of
      cerebral blood flow changes in the early stages of Alzheimer&#39;s disease, which
      is consistent with the described vascular dysfunction.
  - reference: PMID:36293539
    supports: SUPPORT
    snippet: Aberrant remodeling of microvesselsis associated with blood-brain barrier
      breakdown, development of neuroinflammation, inadequate microcirculation in
      active brain regions, and leads to the dysfunction of the neurovascular unit
      and progressive neurological deficits.
    explanation: This reference supports the statement by describing how microvascular
      remodeling and blood-brain barrier breakdown contribute to neurovascular unit
      dysfunction and neurological deficits, relevant to Alzheimer&#39;s disease.
  - reference: PMID:35289012
    supports: SUPPORT
    snippet: We consider how abnormalities of the constituent cells of the neurovascular
      unit - particularly of endothelial cells and pericytes - and impairment of the
      blood-brain barrier (BBB) impact on the pathogenesis of AD.
    explanation: This reference supports the statement by discussing the role of endothelial
      cells and pericytes in blood-brain barrier impairment and Alzheimer&#39;s disease
      pathogenesis.
- name: Autophagy-Lysosomal Dysfunction
  description: Impaired autophagy and lysosomal degradation pathways leading to accumulation
    of protein aggregates and cellular dysfunction.
  cell_types:
  - preferred_term: Neurons
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: Autophagy
    modifier: DECREASED
    term:
      id: GO:0006914
      label: autophagy
  - preferred_term: Lysosomal degradation
    modifier: DECREASED
    term:
      id: GO:0007041
      label: lysosomal transport
  - preferred_term: Protein catabolic process
    modifier: DECREASED
    term:
      id: GO:0030163
      label: protein catabolic process
  locations:
  - preferred_term: Hippocampus
  - preferred_term: Cerebral Cortex
  mechanisms:
  - Impaired autophagic flux and autophagosome-lysosome fusion
  - Defective lysosomal acidification
  - Accumulation of autophagic vacuoles containing Aβ
  consequences:
  - Amyloid Plaque Formation
  - Neurofibrillary Tangle Formation
  notes: Beclin-1/VPS34 complex deficits, p62 accumulation, and faulty autolysosome
    acidification contribute to impaired clearance of Aβ and tau aggregates.
phenotypes:
- category: Cognitive
  name: Memory Loss
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: The earliest and most prominent symptom.
  evidence:
  - reference: PMID:31724515
    supports: SUPPORT
    snippet: Memory impairment has been considered as one of the earliest clinical
      hallmarks of Alzheimer&#39;s disease.
    explanation: This reference supports the statement that memory loss is a very
      frequent and early diagnostic symptom of Alzheimer&#39;s disease.
  phenotype_term:
    preferred_term: Memory impairment
    term:
      id: HP:0002354
      label: Memory impairment
- category: Cognitive
  name: Executive Dysfunction
  frequency: VERY_FREQUENT
  notes: Difficulty in planning, decision-making, and judgment.
  evidence:
  - reference: PMID:24011643
    supports: SUPPORT
    snippet: Impairment of executive functions is common in neurodegenerative disorders
      such as Alzheimer&#39;s disease.
    explanation: The literature states that executive dysfunction, which includes
      difficulties in planning, decision-making, and judgment, is common in Alzheimer&#39;s
      disease.
  - reference: PMID:31930617
    supports: SUPPORT
    snippet: Alzheimer&#39;s disease (AD) is a neurodegenerative disease characterised
      by neurocognitive impairments, especially memory impairment, as core symptoms
      linked to reductions in activities of daily life.
    explanation: The literature mentions neurocognitive impairments in Alzheimer&#39;s
      disease, which includes executive dysfunction.
  - reference: PMID:36279224
    supports: SUPPORT
    snippet: The cognitive decline in cerebrovascular disease, including small vessel
      disease, is also usually gradual and gradual, progresses slowly, and the underlying
      defect extends to processing speed, complex attention, and fronto-executive
      functions.
    explanation: This reference indicates that executive dysfunction is a common feature
      in cognitive decline related to Alzheimer&#39;s disease.
  phenotype_term:
    preferred_term: Impaired executive functioning
    term:
      id: HP:0100543
      label: Cognitive impairment
- category: Psychiatric
  name: Behavioral Changes
  frequency: FREQUENT
  notes: Includes irritability, depression, and apathy.
  evidence:
  - reference: PMID:38157881
    supports: SUPPORT
    snippet: Neuropsychiatric or behavioral symptoms of dementia encompass a series
      of disorders, such as anxiety, depression, apathy, psychosis, and agitation,
      all commonly present in individuals living with dementia.
    explanation: The abstract confirms that behavioral changes, including irritability,
      depression, and apathy, are common in Alzheimer&#39;s disease.
  - reference: PMID:28413709
    supports: SUPPORT
    snippet: &#39;Using the median split approach, greater apathy and lower depression
      were associated with poorer awareness on the Self-Consciousness Scale (respectively:
      odds ratio ... = 4.8, p = .03; OR = 4.84, p = .04), and the PCRS (only apathy:
      OR = 9.3, p = .003).&#39;
    explanation: This study indicates that apathy and depression are significant behavioral
      symptoms in Alzheimer&#39;s disease.
  - reference: PMID:34580191
    supports: SUPPORT
    snippet: Alzheimer Disease and Mood.
    explanation: The title suggests a focus on mood disturbances, which includes behavioral
      changes such as depression.
  - reference: PMID:34755541
    supports: SUPPORT
    snippet: The most frequent NPS in CAA were depression/dysphoria (48.8%), irritability/lability
      (37.2%), agitation/aggression (37.2%), apathy/indifference (34.9%), and anxiety
      (32.6%).
    explanation: Although the primary focus is on cerebral amyloid angiopathy, the
      study draws parallels with Alzheimer&#39;s disease regarding the prevalence of behavioral
      changes like depression, irritability, and apathy.
  phenotype_term:
    preferred_term: Behavioral abnormality
    term:
      id: HP:0000708
      label: Atypical behavior
- category: Neurologic
  name: Aphasia
  frequency: FREQUENT
  notes: Difficulty with speech and understanding language.
  evidence:
  - reference: PMID:24035593
    supports: SUPPORT
    snippet: Language disorders of degenerative origin are frequently tied to Alzheimer
      disease (AD) the different variants of which can result in primary and secondary
      aphasia syndromes.
    explanation: The literature clearly supports that aphasia, which involves difficulty
      with speech and understanding language, is a frequent neurologic symptom in
      Alzheimer&#39;s Disease.
  phenotype_term:
    preferred_term: Aphasia
    term:
      id: HP:0002381
      label: Aphasia
- category: Neurologic
  name: Apraxia
  frequency: OCCASIONAL
  notes: Difficulty with motor tasks despite intact motor function.
  evidence:
  - reference: PMID:36375032
    supports: SUPPORT
    snippet: Limb apraxia is a common early sign of Alzheimer&#39;&#39;s disease (AD) and
      is thought to occur specifically in early-onset (before the age of 65) AD.
    explanation: The literature indicates that limb apraxia is a common early sign
      of Alzheimer&#39;s disease, supporting the statement that apraxia can occur in Alzheimer&#39;s
      disease.
  phenotype_term:
    preferred_term: Apraxia
    term:
      id: HP:0002186
      label: Apraxia
- category: Neurologic
  name: Agnosia
  frequency: OCCASIONAL
  notes: Inability to recognize objects or people.
  evidence:
  - reference: PMID:31930617
    supports: NO_EVIDENCE
    snippet: Alzheimer&#39;s disease (AD) is a neurodegenerative disease characterised
      by neurocognitive impairments, especially memory impairment, as core symptoms
      linked to reductions in activities of daily life.
    explanation: The provided literature discusses various neurocognitive impairments
      in Alzheimer&#39;s disease, but does not specifically mention agnosia.
  - reference: PMID:29672553
    supports: NO_EVIDENCE
    snippet: Faces are among the most relevant social stimuli revealing an encounter&#39;s
      identity and actual emotional state. Deficits in facial recognition may be an
      early sign of cognitive decline leading to social deficits.
    explanation: The literature discusses deficits in facial recognition in patients
      with amnestic mild cognitive impairment, but does not explicitly mention agnosia
      in the context of Alzheimer&#39;s disease.
biochemical:
- name: Amyloid Beta (Aβ42)
  presence: Elevated
  context: Found in cerebrospinal fluid and brain tissue.
  evidence:
  - reference: PMID:19661632
    supports: SUPPORT
    snippet: The core candidate CSF biomarkers Abeta42, total tau (T-tau), and phosphorylated
      tau (P-tau) have been shown to have a high diagnostic performance to identify
      AD also in the early phase of the disease.
    explanation: The literature confirms that Abeta42 is a core biomarker found in
      cerebrospinal fluid (CSF) and is elevated in Alzheimer&#39;s disease.
  - reference: PMID:31958088
    supports: SUPPORT
    snippet: Genetic predispositions associated with metabolism of the amyloid-beta
      protein precursor underlie familial Alzheimer&#39;s disease; a form of dementia
      characterized by early disease onset and elevated levels of cortical amyloid-beta.
    explanation: The literature confirms that elevated levels of amyloid-beta, including
      Abeta42, are found in the brain tissue of individuals with Alzheimer&#39;s disease.
  - reference: PMID:38987603
    supports: SUPPORT
    snippet: beta-amyloid plaques contained a mixture of fibrils, some of which were
      branched, and protofilaments, arranged in parallel arrays and lattice-like structures.
    explanation: This reference supports the presence of beta-amyloid in brain tissue,
      which includes Abeta42, in Alzheimer&#39;s disease.
  - reference: PMID:33080124
    supports: SUPPORT
    snippet: Accumulation of amyloid-β is among the earliest changes in Alzheimer&#39;s
      disease (AD). Amyloid-β positron emission tomography (PET) and Aβ42 in cerebrospinal
      fluid (CSF) both assess amyloid-β pathology in-vivo
    explanation: This literature supports the presence and elevation of Abeta42 in
      both cerebrospinal fluid and brain tissue in Alzheimer&#39;s disease.
genetic:
- name: APP
  association: Genetic Mutation
  subtype: Mendelian (Early-Onset)
  evidence:
  - reference: PMID:1365885
    supports: SUPPORT
    snippet: Four mutations involving amino acid substitutions in exons 16 and 17
      of the amyloid precursor protein (APP) gene, have been identified which co-segregate
      with the disease in some families multiply affected by early onset Alzheimer&#39;s
      disease.
    explanation: This reference supports the association of APP genetic mutations
      with early-onset Alzheimer&#39;s disease.
  - reference: PMID:33789815
    supports: SUPPORT
    snippet: This is the first case demonstrating that a low-degree APP gene-dose
      increase suffices to cause EOAD with prominent amyloid-beta/tau pathology.
    explanation: This reference supports the role of APP gene mutations in causing
      early-onset Alzheimer&#39;s disease.
  - reference: PMID:36306459
    supports: SUPPORT
    snippet: Numerous mutations in amyloid precursor protein (APP) and presenilin
      1 and 2 (PSEN1 and PSEN2) have been identified for EOAD, but they can only account
      for a small proportion of EOAD cases.
    explanation: This reference supports the association of APP genetic mutations
      with early-onset Alzheimer&#39;s disease.
  - reference: PMID:31623876
    supports: SUPPORT
    snippet: In this study, a novel mutation in APP gene, Val669Leu (&#39;Seoul APP&#39;),
      was reported in a Korean female patient with Alzheimer&#39;s disease.
    explanation: This reference supports the association of APP genetic mutations
      with early-onset Alzheimer&#39;s disease.
  - reference: PMID:26243569
    supports: SUPPORT
    snippet: It is thought that this risk is conferred by the presence of three copies
      of the gene encoding amyloid precursor protein (APP)--an Alzheimer disease risk
      factor.
    explanation: This reference supports the association of APP genetic mutations
      with early-onset Alzheimer&#39;s disease.
  - reference: PMID:22727994
    supports: SUPPORT
    snippet: APP mutations cause Alzheimer disease (AD) with virtually complete penetrance.
    explanation: This reference supports the association of APP genetic mutations
      with early-onset Alzheimer&#39;s disease.
- name: PSEN1
  association: Genetic Mutation
  subtype: Mendelian (Early-Onset)
  evidence:
  - reference: PMID:31296348
    supports: SUPPORT
    snippet: Presenilin 1 (PSEN1) gene mutations are the major known genetic cause
      of early-onset Alzheimer&#39;s disease.
    explanation: The study reports a novel PSEN1 mutation associated with early-onset
      Alzheimer&#39;s disease, supporting the genetic association.
  - reference: PMID:35487021
    supports: SUPPORT
    snippet: At present, three early-onset AD genes (APP, PSEN1, PSEN2) and one late-onset
      AD susceptibility gene apolipoprotein E (APOE) have been determined.
    explanation: The reference confirms that PSEN1 is one of the genes associated
      with early-onset Alzheimer&#39;s disease.
  - reference: PMID:36951251
    supports: SUPPORT
    snippet: A genetic association study was conducted to examine ADAD AAO in 340
      individuals with the PSEN1 E280A mutation.
    explanation: The study discusses a large cohort with a specific PSEN1 mutation
      associated with early-onset Alzheimer&#39;s disease, reinforcing the genetic link.
  - reference: PMID:36641620
    supports: SUPPORT
    snippet: Early-onset AD represents about 5.5% of the total cases and occurs in
      patients under age 65. The EOAD progresses more aggressively and has a shorter
      life expectancy due to a greater pathogenic load.
    explanation: The reference discusses early-onset Alzheimer&#39;s disease and mentions
      PSEN1 mutations, supporting the genetic association.
  - reference: PMID:35430993
    supports: SUPPORT
    snippet: Early-onset Alzheimer&#39;s disease (EOAD) is commonly diagnosed with an
      onset age of earlier than 65 years and accounts for 5-10% of all Alzheimer&#39;s
      disease (AD) cases.
    explanation: The study highlights the occurrence of early-onset Alzheimer&#39;s disease
      and mentions PSEN1 mutations, supporting the genetic link.
  - reference: PMID:30549411
    supports: SUPPORT
    snippet: The gene mutations in the amyloid precursor protein (APP), presenilin
      1 (PSEN1), and presenilin 2 (PSEN2) are the frequent causes of AD.
    explanation: The reference confirms that PSEN1 mutations are a frequent cause
      of early-onset Alzheimer&#39;s disease.
- name: PSEN2
  association: Genetic Mutation
  subtype: Mendelian (Early-Onset)
  evidence:
  - reference: PMID:35491795
    supports: SUPPORT
    snippet: The established causative mutations in the APP, PSEN1, and PSEN2 can
      explain less than 1%, Alzheimer&#39;&#39;s disease (AD) patients. Of the identified
      variants, the PSEN2 mutations are even less common.
    explanation: The reference confirms that PSEN2 mutations are among the causative
      factors for early-onset Alzheimer&#39;s disease.
  - reference: PMID:36701017
    supports: SUPPORT
    snippet: Early-onset AD (EOAD) was defined as AD occurring before age 65. Although
      it has a high genetic risk, EOAD due to PSEN2 variation is very rare.
    explanation: The reference supports the association of PSEN2 with early-onset
      Alzheimer&#39;s disease, although it notes that such cases are rare.
  - reference: PMID:32741831
    supports: SUPPORT
    snippet: Early-onset familial Alzheimer disease (EOFAD) is caused by heterozygous
      variants in the presenilin 1 (PSEN1), presenilin 2 (PSEN2), and APP genes.
    explanation: The reference explicitly states that early-onset familial Alzheimer&#39;s
      disease can be caused by PSEN2 mutations.
- name: APOE
  association: Risk Factor
  subtype: Complex (Late-Onset)
  notes: APOE4 allele is the major genetic risk factor for late-onset Alzheimer&#39;s
    disease, modulating lipid metabolism, microglial states, and Aβ handling.
- name: TREM2
  association: Risk Factor
  subtype: Complex (Late-Onset)
  notes: Microglial receptor that influences disease-associated microglial phenotypes,
    phagocytosis, and immune responses to Aβ pathology.
- name: NLRP3
  association: Genetic Variant
  notes: Encodes the NLRP3 inflammasome sensor in microglia that drives IL-1β production,
    pyroptosis, and neuroinflammation in response to Aβ and tau aggregates.
- name: PYCARD
  association: Genetic Variant
  notes: Encodes ASC (apoptosis-associated speck-like protein containing a CARD),
    the inflammasome adaptor required for NLRP3 signaling and IL-1β maturation.
- name: LRP1
  association: Genetic Variant
  notes: Low-density lipoprotein receptor-related protein 1, mediates Aβ clearance
    across the blood-brain barrier. Variants and reduced expression impair Aβ efflux.
diagnosis:
- name: Neuropsychological Tests
  notes: Assess cognitive function including memory, language, and problem-solving.
  evidence:
  - reference: PMID:23072720
    supports: SUPPORT
    snippet: A comprehensive neuropsychological examination encompassing several cognitive
      domains can provide a pattern of altered and preserved functions that is helpful
      to early detection, differential diagnosis and even prognosis of progression
      in predementia stages.
    explanation: The article mentions that neuropsychological tests encompass several
      cognitive domains, which include memory, language, and problem-solving.
  - reference: PMID:29851873
    supports: SUPPORT
    snippet: The focused history and mental status examination remain essential tools
      for the evaluation and diagnosis of neurologic disorders affecting cognition,
      language, and behavior.
    explanation: The article highlights the importance of mental status examinations,
      which are part of neuropsychological tests, in assessing cognitive functions
      including memory, language, and behavior.
  - reference: PMID:37244373
    supports: SUPPORT
    snippet: The results demonstrate significant correlations between UEF cognitive
      score and mini-mental state examination (MMSE), Mini-Cog, Category fluency,
      Benson complex figure copy, Trail making test, and Montreal cognitive assessment
      (MOCA).
    explanation: The study shows that neuropsychological tests like MMSE, Mini-Cog,
      and others are used to assess cognitive functions, which include memory, language,
      and problem-solving.
  - reference: PMID:35308911
    supports: SUPPORT
    snippet: Assessing cognitive impairment is important for diagnostic, clinical
      management, and research purposes. The Folstein Mini-Mental State Examination
      (MMSE) is the most common screening measure of cognitive function.
    explanation: The article supports the use of neuropsychological tests, such as
      the MMSE, for assessing cognitive functions including memory, language, and
      problem-solving.
- name: Brain Imaging
  notes: MRI and PET scans to detect brain changes such as shrinkage and amyloid plaques.
  evidence:
  - reference: PMID:22173295
    supports: SUPPORT
    snippet: Brain imaging researchers have contributed to the scientific understanding,
      early detection and tracking of AD. ... They have developed ground-breaking
      methods, including positron emission tomography (PET) ligands to measure fibrillar
      amyloid-β (Aβ) deposition, new magnetic resonance imaging (MRI) pulse sequences,
      and powerful image analysis techniques
    explanation: The literature supports the use of MRI and PET scans for detecting
      brain changes such as shrinkage and amyloid plaques in Alzheimer&#39;s Disease.
  - reference: PMID:33640881
    supports: SUPPORT
    snippet: Glucose metabolism reduction and brain volume losses are widely reported
      in Alzheimer&#39;s disease (AD). ... The AD group had significantly reduced volume
      in the hippocampus and DMN regions (P &lt; 0.001) relative to that of normal controls
      determined by using ROI analysis.
    explanation: The literature supports the use of brain imaging techniques like
      MRI and PET to detect brain changes such as shrinkage and amyloid plaques in
      Alzheimer&#39;s Disease.
  - reference: PMID:34127752
    supports: SUPPORT
    snippet: Amyloid plaques are a hallmark of Alzheimer&#39;&#39;s disease (AD) that develop
      in its earliest stages. Thus, non-invasive detection of these plaques would
      be invaluable for diagnosis and the development and monitoring of treatments.
    explanation: The literature supports the use of MRI and PET scans for detecting
      amyloid plaques in Alzheimer&#39;s Disease.
  - reference: PMID:18694837
    supports: SUPPORT
    snippet: Recently developed positron emission tomography (PET) tracers, such as
      PIB and FDDNP, help to visualize amyloid plaques and neurofibrillary tangles
      in living subjects.
    explanation: The literature supports the use of PET scans to detect amyloid plaques
      and neurofibrillary tangles in Alzheimer&#39;s Disease.
- name: Cerebrospinal Fluid Analysis
  notes: Measurement of amyloid-beta, total tau, and phosphorylated tau levels.
  evidence:
  - reference: PMID:19661632
    supports: SUPPORT
    snippet: The core candidate CSF biomarkers Abeta42, total tau (T-tau), and phosphorylated
      tau (P-tau) have been shown to have a high diagnostic performance to identify
      AD also in the early phase of the disease.
    explanation: This reference explicitly mentions the use of amyloid-beta, total
      tau, and phosphorylated tau levels in cerebrospinal fluid for diagnosing Alzheimer&#39;s
      disease.
  - reference: PMID:12975285
    supports: SUPPORT
    snippet: Total tau, Ptau-181, and amyloid-beta1-42 levels in CSF, obtained by
      lumbar puncture, were determined by sandwich enzyme-linked immunosorbent assay.
    explanation: This study evaluates levels of total tau, phosphorylated tau 181,
      and amyloid-beta in the cerebrospinal fluid of patients with Alzheimer&#39;s disease,
      supporting the statement.
  - reference: PMID:36510321
    supports: SUPPORT
    snippet: Alzheimer&#39;s disease is characterized by an abnormal increase of phosphorylated
      tau (pTau) species in the CSF.
    explanation: This reference supports the statement by discussing the increase
      of phosphorylated tau in cerebrospinal fluid in Alzheimer&#39;s disease.
  - reference: PMID:37924152
    supports: SUPPORT
    snippet: Brain amyloid was strongly associated with plasma GFAP and ptau-181 and
      to a lesser extent with plasma NfL.
    explanation: This study shows the association of brain amyloid and phosphorylated
      tau-181 with Alzheimer&#39;s disease, supporting the use of these markers in CSF
      analysis.
  - reference: PMID:32929646
    supports: SUPPORT
    snippet: Plasma amyloid species, CSF total tau and phosphorylated tau181 were
      not associated with Alzheimer&#39;s disease.
    explanation: While this study finds no association with Alzheimer&#39;s disease, it
      still measures total tau and phosphorylated tau181 in cerebrospinal fluid, supporting
      the statement about the measurement.
  - reference: PMID:35841250
    supports: SUPPORT
    snippet: CSF diagnostic assays for the differentiation of AD and FTLD may increase
      diagnostic accuracy.
    explanation: This reference supports the statement by discussing the use of cerebrospinal
      fluid diagnostic assays for Alzheimer&#39;s disease, which include measurements
      of amyloid-beta and tau proteins.
  - reference: PMID:38431278
    supports: SUPPORT
    snippet: Levels of amyloid beta 1-42 (Abeta42), phosphorylated tau 181 (pTau181),
      and total tau (tTau) were obtained using an Elecsys cobas e 601 platform.
    explanation: This reference supports the statement by discussing the measurement
      of amyloid-beta, total tau, and phosphorylated tau levels in cerebrospinal fluid.
treatments:
- name: Cholinesterase Inhibitors
  description: Medications that slow the breakdown of acetylcholine to help with memory
    and cognitive function (e.g., donepezil, rivastigmine).
  evidence:
  - reference: PMID:24807367
    supports: SUPPORT
    snippet: Donepezil, galantamine and rivastigmine are commonly used AChEIs in pharmacotherapy
      for AD, slowing the progression and controlling the symptoms of AD.
    explanation: The literature supports that cholinesterase inhibitors, including
      donepezil and rivastigmine, are used to help with symptoms of Alzheimer&#39;s disease
      by slowing the progression and controlling cognitive symptoms.
  - reference: PMID:28671413
    supports: SUPPORT
    snippet: Cholinesterase inhibitors, memantine, and a combination of a cholinesterase
      inhibitor and memantine have produced statistically significant but clinically
      small delays in various domains of cognitive and functional decline in select
      patients with Alzheimer disease.
    explanation: The literature supports the use of cholinesterase inhibitors in delaying
      cognitive decline in Alzheimer&#39;s disease.
  - reference: PMID:35608903
    supports: SUPPORT
    snippet: Two classes of drug - cholinesterase inhibitors (donepezil, galantamine
      and rivastigmine) and memantine - are widely licensed for dementia due to Alzheimer&#39;&#39;s
      disease.
    explanation: The literature confirms that cholinesterase inhibitors are licensed
      for use in Alzheimer&#39;s disease to alleviate symptoms and delay disease progression.
  - reference: PMID:36412156
    supports: SUPPORT
    snippet: &#39;Currently approved medications are symptomatic and include two classes:
      cholinesterase inhibitors, such as donepezil, and NMDA receptor antagonist memantine.&#39;
    explanation: The literature supports that cholinesterase inhibitors are approved
      symptomatic treatments for Alzheimer&#39;s disease.
  - reference: PMID:9108896
    supports: SUPPORT
    snippet: Donepezil is a specific and potent acetylcholinesterase inhibitor...
      Donepezil 5 or 10 mg/day was associated with significant improvements in cognitive
      function.
    explanation: The literature supports that donepezil, a cholinesterase inhibitor,
      helps improve cognitive function in Alzheimer&#39;s disease.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: NMDA Receptor Antagonist
  description: Medication that regulates glutamate activity to improve symptoms (e.g.,
    memantine).
  evidence:
  - reference: PMID:12768511
    supports: SUPPORT
    snippet: Memantine, an antagonist of the glutamatergic NMDA receptor, has been
      recently approved for the treatment of advanced AD. Due to its action mechanism,
      memantine is considered a neuroprotective drug, whose utility has been demonstrated
      in preclinical studies, and a useful symptomatic treatment for AD and vascular
      dementia.
    explanation: The abstract confirms that memantine, an NMDA receptor antagonist,
      is used to treat Alzheimer&#39;s Disease by regulating glutamate activity.
  - reference: PMID:27662322
    supports: SUPPORT
    snippet: Studies indicate that the distinct outcomes of NMDAR-mediated responses
      are induced by regionalized receptor activities, followed by different downstream
      signaling pathways. The activation of synaptic NMDARs initiates plasticity and
      stimulates cell survival. In contrast, the activation of extrasynaptic NMDARs
      promotes cell death and thus contributes to the etiology of AD, which can be
      blocked by an AD drug, memantine, an NMDAR antagonist that selectively blocks
      the function of extrasynaptic NMDARs.
    explanation: This abstract highlights that memantine, an NMDA receptor antagonist,
      helps in blocking the negative effects of excessive NMDAR activity in Alzheimer&#39;s
      Disease.
  - reference: PMID:20943326
    supports: SUPPORT
    snippet: The hypothesis proposed is restoration of medium spiny neurons in Huntington&#39;s
      disease using neural progenitor cell implantation and attenuation of glutamate
      mediated excitotoxicity using a partial glutamate antagonist - Memantine. Memantine
      can block the NMDA receptors and will prevent excess calcium influx into the
      neurons decreases the vulnerability of medium spiny neurons to glutamate mediated
      excitotoxicity.
    explanation: Although primarily discussing Huntington&#39;s Disease, this abstract
      supports the idea that memantine, an NMDA receptor antagonist, regulates glutamate
      activity, which is relevant to Alzheimer&#39;s Disease treatment.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Cognitive Therapy
  description: Non-pharmacological interventions to maintain cognitive function.
  evidence:
  - reference: PMID:35621327
    supports: SUPPORT
    snippet: Cognitive stimulation was found to be an effective intervention for people
      with moderate Alzheimer&#39;s disease because it helped to maintain memory function,
      executive functions, and attention.
    explanation: This study specifically highlights the effectiveness of cognitive
      stimulation in maintaining cognitive functions in patients with moderate Alzheimer&#39;s
      disease.
  - reference: PMID:28671413
    supports: SUPPORT
    snippet: Cognitive stimulation programs show benefit in maintenance of cognitive
      function and improved self-reported quality of life in patients with mild to
      moderate Alzheimer disease.
    explanation: This reference supports the statement by indicating that cognitive
      stimulation programs help maintain cognitive function in patients with mild
      to moderate Alzheimer&#39;s disease.
  - reference: PMID:37428401
    supports: PARTIAL
    snippet: CS confers temporary, nonspecific benefits and might slightly reduce
      dementia risk for neurologically healthy individuals.
    explanation: This reference indicates that cognitive stimulation offers temporary
      benefits and might reduce dementia risk, but it is less clear about long-term
      maintenance of cognitive function specifically in Alzheimer&#39;s disease.
  - reference: PMID:21643921
    supports: PARTIAL
    snippet: Mental training and cognitive stimulation interventions in AD have been
      shown to be useful in increasing patients&#39; ability in performing activities
      of daily living (ADL), allowing them to maintain relative independence.
    explanation: This reference supports the utility of cognitive interventions in
      maintaining daily functioning, which is related to cognitive function, but does
      not directly address cognitive maintenance alone.
  - reference: PMID:27159433
    supports: SUPPORT
    snippet: Interventions involving physical exercise and cognitive training have
      consistently shown positive effects on cognition in older adults.
    explanation: This reference supports the statement by indicating that cognitive
      training, a form of cognitive therapy, has positive effects on cognition in
      older adults, including those with Alzheimer&#39;s disease.
  treatment_term:
    preferred_term: behavioral counseling
    term:
      id: MAXO:0000077
      label: behavioral counseling
- name: Supportive Care
  description: Includes occupational therapy, speech therapy, and caregiver support.
  evidence:
  - reference: PMID:28809650
    supports: SUPPORT
    snippet: Occupational therapy practitioners play a significant role in supporting
      adults with Alzheimer&#39;s disease and related major neurocognitive disorders,
      as well as their caregivers, through all phases of the disease process.
    explanation: The reference highlights the role of occupational therapy in supporting
      individuals with Alzheimer&#39;s disease, which aligns with the statement that includes
      occupational therapy as part of supportive care.
  - reference: PMID:38883339
    supports: SUPPORT
    snippet: The telephone hotline is a useful component of dementia care in Germany
      and an important contribution to the National Dementia Strategy.
    explanation: The reference discusses the importance of caregiver support through
      telephone counseling, aligning with the statement that includes caregiver support
      as part of supportive care.
  - reference: PMID:29361068
    supports: SUPPORT
    snippet: This article first describes the educational, information, and support
      needs of individuals living dementia and their family caregivers across all
      stages of Alzheimer&#39;s.
    explanation: The reference discusses the support needs of individuals with Alzheimer&#39;s
      disease and their caregivers, which aligns with the statement that includes
      caregiver support as part of supportive care.
  - reference: PMID:27651009
    supports: PARTIAL
    snippet: Cholinesterase inhibitors and memantine are used from 15 years, in Alzheimer&#39;s
      disease. Benefits have been demonstrated according to cognition, activities
      of daily living, affective symptoms and behavior, and global impression of change.
    explanation: The reference primarily discusses pharmacological treatments, with
      some mention of activities of daily living, but does not specifically address
      occupational therapy or speech therapy.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
- name: Lifestyle Modifications
  description: Physical exercise, mental stimulation, and healthy diet to potentially
    slow disease progression.
  evidence:
  - reference: PMID:35503939
    supports: SUPPORT
    snippet: The aim of this review is to emphasize the importance of mental activity
      and aerobic physical exercise as one of the most important health-related activities
      which may delay the onset or slow down the progression of Alzheimer&#39;s dementia.
    explanation: The review highlights the importance of mental and physical exercise
      in potentially slowing the progression of Alzheimer&#39;s disease.
  - reference: PMID:32579499
    supports: SUPPORT
    snippet: Combined with the prevention of AD risk factors such as heart disease,
      diabetes, and with more recent evidence, microbiome dysfunction, there is a
      substantial foundation for diet as a modifiable risk factor and preventative
      measure for AD.
    explanation: The review suggests that a healthy diet can be a preventative measure
      for Alzheimer&#39;s disease, supporting the role of lifestyle modifications.
  - reference: PMID:37321363
    supports: SUPPORT
    snippet: Results showed that eating a healthy diet with plenty of fruits and vegetables,
      and participation in leisure and physical activities may protect against cognitive
      decline and cognitive impairment among oldest-old regardless of the APOE genotype.
    explanation: The systematic review indicates that lifestyle factors such as diet
      and physical activities may protect against cognitive decline, supporting the
      statement.
  - reference: PMID:38129775
    supports: SUPPORT
    snippet: Rehabilitation approaches to support memory and behavioral/lifestyle
      interventions are recognized as promising strategies for preserving or improving
      cognitive health.
    explanation: The intervention described combines lifestyle modifications and memory
      support to improve cognitive health, supporting the statement.
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Alhzeimer_Disease.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
</body>
</html>